An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2017 Planned End Date changed from 1 Apr 2023 to 1 Dec 2023.
- 16 Nov 2017 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2023.